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Aldo-keto reductases (AKRs) are mostly monomeric enzymes
which fold into a highly conserved (/)8 barrel, while their
substrate specificity and inhibitor selectivity are determined
by interaction with residues located in three highly variable
external loops. The closely related human enzymes aldose
reductase (AR or AKR1B1) and AKR1B10 are of biomedical
interest because of their involvement in secondary diabetic
complications (AR) and in cancer, e.g. hepatocellular
carcinoma and smoking-related lung cancer (AKR1B10).
After characterization of the IC50 values of both AKRs with a
series of polyhalogenated compounds, 2,20,3,30,5,50,6,60-octa-
fluoro-4,40-biphenyldiol (JF0064) was identified as a lead
inhibitor of both enzymes with a new scaffold (a 1,10-biphenyl-
4,40-diol). An ultrahigh-resolution X-ray structure of the
AR–NADP+–JF0064 complex has been determined at 0.85 A˚
resolution, allowing it to be observed that JF0064 interacts
with the catalytic residue Tyr48 through a negatively charged
hydroxyl group (i.e. the acidic phenol). The non-competitive
inhibition pattern observed for JF0064 with both enzymes
suggests that this acidic hydroxyl group is also present in the
case of AKR1B10. Moreover, the combination of surface
lysine methylation and the introduction of K125R and V301L
mutations enabled the determination of the X-ray crystallo-
graphic structure of the corresponding AKR1B10–NADP+–
JF0064 complex. Comparison of the two structures has
unveiled some important hints for subsequent structure-based
drug-design efforts.
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PDB references: AR–
NADP+–JF0064 complex,
4igs; AKR1B10–NADP+–
JF0064 complex, 4icc
1. Introduction
Human aldose reductase (AR; also known as AKR1B1)
enzymatically transforms excessive cytosolic glucose into
sorbitol through hydride donation from its cofactor NADPH
(which becomes NADP+) and proton donation from the
enzyme. Sorbitol is a molecule which poorly penetrates cell
membranes and is sometimes slowly metabolized. Therefore,
hyperglycaemia may cause intracellular accumulation of
sorbitol and its metabolite fructose, which may produce
osmotic swelling and cell dysfunction. This simple paradigm
configured the ‘Osmotic Hypothesis’ for diabetic complica-
tions and was armed with positive pre-clinical results on
prototype AR inhibitors (ARIs), as researchers worldwide
have targeted secondary diabetic complications with ARIs for
four decades. However, most trial outcomes have been
disappointing, even as scientific evidence that AR plays a key
pathogenic role in diabetes has continued to mount. In cells
cultured under high-glucose conditions, many studies have
demonstrated similarly AR-dependent increases in oxidative
stress, confirming AR as an important factor in the patho-
genesis of many diabetic complications. Also, ARIs may be
able to prevent or delay the onset of cardiovascular compli-
cations such as ischaemia/reperfusion injury, atherosclerosis
and atherothrombosis related to secondary diabetic compli-
cations (Tang et al., 2012). Evidence is now strong that the
Osmotic Hypothesis and the nerve sorbitol endpoint were
misleading. Current recognition of the pathogenic importance
of oxidative stress and its strong link to metabolic flux through
AR have led to a revitalized ‘Metabolic Flux Hypothesis’
emphasizing cofactor rather than polyol turnover (Oates,
2008). Moreover, AR has recently been related to a number of
inflammatory diseases such as atherosclerosis, sepsis, asthma,
allergic rhinitis and uveitis (Ramana & Srivastava, 2010;
Yadav et al., 2013). Furthermore, AR has been shown to be
involved in cancer, especially colon and hepatocellular carci-
nomas (Tammali et al., 2011; Zeindl-Eberhart et al., 2004), and
AR inhibition has been reported to prevent colon cancer
metastasis (Tammali et al., 2011).
AKR1B10 is an AR homologue (sharing 71% sequence
identity) that is primarily found in the colon, small intestine
and adrenal glands, and is overexpressed in lung and liver
cancers, amongst others (Fukumoto et al., 2005; Ruiz et al.,
2009; Wang et al., 2009; Zeindl-Eberhart et al., 2004). This
enzyme is able to catalyze the reduction of anticancer and
potentially cytostatic drugs, and of different kinds of alde-
hydes, but does not catalyze the reduction of glucose (Barski
et al., 2008; Gallego et al., 2006). AKR1B10 can reduce
retinaldehyde to retinol, thus depleting intracellular retinoic
acid (RA). AKR1B10 may impact on the carcinogenesis
process through different pathways, e.g. the control of RA
signalling (Gallego et al., 2007; Penning, 2005; Quinn et al.,
2008; Ruiz et al., 2009, 2012), detoxification of reactive lipid
aldehydes, promotion of lipid synthesis by association with
acetyl-CoA carboxylase and regulation of protein isopreny-
lation (Chung et al., 2012; Ma et al., 2008; Wang et al., 2010). It
is especially noteworthy that tobacco smoking mediates
AKR1B10 overexpression in the airway epithelia of smokers
with no previous evidence of lung cancer. In the context of
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Figure 1
(a) Chemical structures of some representative ARIs and AKR1B10 inhibitors.
these observations and the link of AKR1B10 with the meta-
bolism of retinoids and with lung cancer, the smoking-induced
up-regulation of AKR1B10 may be an early process in the
multiple events leading to lung cancer (Wang et al., 2010).
AKR1B10 also catalyzes the reduction of anticancer drugs
such as daunorubicin, oracin and idarubicin, which is also
thought to cause cancer cell chemoresistance. Thus, this
enzyme has been recognized not only as a potential diagnostic
and/or prognostic marker, but also as a target for the
prevention and treatment of different types of cancer (Soda,
Hu et al., 2012).
Most ARIs contain a carboxylic acid moiety or a cyclic
imide group (Fig. 1a). The best known of the cyclic imide
compounds, sorbinil, has been thoroughly analyzed by struc-
ture determination of its ternary complex with AR and
NADP+ and also by several clinical studies. Other examples
of this group of compounds include fidarestat and ranirestat.
There are also numerous compounds that incorporate a
carboxylic acid moiety, such as tolrestat, ponalrestat and
zopolrestat. The cyclic imide or carboxylic acid moiety binds
to an essentially hydrophilic area of the active site of AR, the
anion-binding pocket, which involves the catalytic residues
Tyr48 and His110, along with Trp111 and the positively
charged nicotinamide moiety of the cofactor NADP+. Another
feature common to the various inhibitors is the presence of
one or more aromatic groups, which bind in a hydrophobic
pocket of AR bordered by the Trp111, Phe122 and Leu300
residues through hydrogen bonding and hydrophobic contacts.
This constitutes a second important pharmacophoric
requirement for inhibitors binding to AR. In most cases, this
second pocket, known as the ‘specificity pocket’, is open and
is well differentiated from the anion-binding pocket. All of
these features of the ARIs have been extensively reviewed
(Changjin, 2013; El-Kabbani & Podjarny, 2007; Oates, 2008).
Inhibitors containing the carboxylic acid or cyclic imide
group exhibit similar in vitro activities but different in vivo
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Figure 1 (continued)
(b) Chemical structures of the parent synthesis scaffold, marine sponge natural products and the JF inhibitor series. (c) The JF0064 chemical structure
with the numbering used in both PDB entries. Chemical structures were prepared with ChemDraw.
activities. The carboxylic acid-containing inhibitors have lower
in vivo activity, which has been attributed to the relatively low
pKa value of the carboxyl group, thus causing ionization at
physiological pH and an inability to traverse cell membranes.
Conversely, cyclic imides have higher pKa values and are only
partially ionized at physiological pH, thus being able to pass
through cell membranes and therefore having better phar-
macokinetic properties (El-Kabbani, Ruiz et al., 2004).
Regardless of the numerous efforts that have been made in
recent decades, to date epalrestat (with a carboxylic acid
moiety) is the only ARI that is commercially available (but
only in Japan), while fidarestat (with a cyclic imide) has
already undergone phase III clinical trials for diabetic
neuropathy and was found to be safe, although clinically not
very effective. In many cases the failure of new candidates
can be attributed to poor pharmacokinetic properties and/or
unacceptable side effects (Ramunno et al., 2012). The advan-
tage of the cyclic imide compounds over the carboxylic acids is
that they can be uncharged during transport, thus improving
their pharmacokinetic properties, and become charged when
binding to the enzyme owing to interactions with specific
enzyme groups favouring the ionization of the inhibitor
(El-Kabbani, Darmanin et al., 2004).
Regarding the selectivity of ARIs with respect to other
enzymes of the AKR superfamily, to date the only off-target
protein analyzed has been aldehyde reductase (or AKR1A1;
Barski et al., 2008; El-Kabbani & Podjarny, 2007; Steuber et al.,
2008). Only some recent studies have addressed the selectivity
of ARIs versus AKR1B10. Gallego et al. (2007) reported that
tolrestat, an ARI of the carboxylic acid type, inhibited AR-
catalyzed and AKR1B10-catalyzed retinaldehyde reduction,
and they also resolved the three-dimensional X-ray structure
of AKR1B10 in complex with NADP+ and tolrestat. Verma et
al. (2008) determined the potency of fibrate-mediated inhibi-
tion of the carbonyl reduction catalyzed by an AKR1B10 wild-
type and C299S mutant, and compared it with the known
ARIs zopolrestat, EBPC and sorbinil. They showed that these
ARIs followed pure non-competitive inhibition kinetics with
AKR1B10. Several recent studies have found new types of
AKR1B10 inhibitors that are selective for this enzyme and not
for AR: steroids (cholanic acid derivatives, C21-, C19- and C18-
steroids), curcuminoids, chromene derivatives, oleanolic acid,
some nonsteroidal anti-inflammatory drugs and caffeic acid
phenethyl ester (CAPE) derivatives (Fig. 1a; Dı´ez-Dacal et al.,
2011; Endo, Matsunaga, Kuwata et al., 2010; Endo et al., 2009;
Endo, Matsunaga, Soda et al., 2010; Matsunaga et al., 2009;
Soda, Hu et al., 2012; Takemura et al., 2011).
In this work, we have screened a series of polyhalogenated
ARIs lacking the usual carboxylic acid or cyclic imide moiety
through determination of their IC50 values against AR and
AKR1B10. Some of these compounds have previously been
characterized as ARIs (de la Fuente et al., 2003). JF0064 has
emerged as a novel lead compound with a new scaffold and its
Ki value has been determined for AR and AKR1B10, iden-
tifying it as a non-competitive inhibitor. X-ray structures were
obtained for both the AR and AKR1B10 holoenzymes with
JF0064, observing its binding mode (noting a negatively
charged hydroxyl group in the inhibitor) and finding inter-
esting hints for drug design based on this compound. The AR
structure highlights the importance of ultrahigh resolution to
identify the unexpected protonation state of the inhibitor that
is critical for its binding. Hence, overall this work represents
another step forward in this topic of pharmacological impor-
tance, as AR is a target for antidiabetes intervention and both
AR and AKR1B10 have been identified as targets for anti-
cancer therapy (Liu et al., 2009).
2. Materials and methods
2.1. Site-directed mutagenesis and purification of
recombinant enzymes
The K125R and V301L mutants of AKR1B10 were
obtained using wild-type AKR1B10 cDNA cloned into
pET30-Xa/LIC (Novagen) as a template. All reactions were
performed in a DNA thermal cycler with Phusion High-
Fidelity DNA Polymerase (Thermo Scientific). To introduce
the V301L mutation, the QuikChange Site-Directed Muta-
genesis Kit (Stratagene) method was used with the following
primers: GCCTGTAACCTGTTGCAATCC (forward; base
pairs 931–951) and ATTGCAACAGGTTACAGGCCC
(reverse complement; base pairs 929–949). To introduce the
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Table 1
Data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Protein AR–NADP+–JF0064
mAKR1B10 K125R/
V301L–NADP+–JF0064
Data collection
X-ray source, beamline SLS, beamline X06SA Home source
Wavelength (A˚) 0.70849 1.54178
Space group P21 P31
Unit-cell parameters
(A˚, )
a = 49.54, b = 66.88,
c = 47.53,  = 91.66
a = b = 79.34,
c = 50.17
Data-collection
temperature (K)
100 100
Resolution range (A˚) 30.86–0.85 (0.88–0.85) 23.57–1.75 (1.81–1.75)
No. of observations 1226806 157603
No. of unique reflections 498513 35357
Completeness (%) 93.0 (75.9) 99.0 (94.4)
Rmerge (%) 3.3 (31.1)† 6.7 (32.6)
Mean I/(I) 23.3 (2.43) 21.9 (2.94)
Multiplicity 2.5 (1.9) 4.5 (2.6)
Model used for MR 1us0 1zua
Refinement statistics
Resolution range (A˚) 30.86–0.85 (0.86–0.85) 23.57–1.75 (1.80–1.75)
R factor (%) 13.48 (22.98) 16.20 (14.76)
Rfree (%) 14.33 (22.97) 18.64 (17.86)
No. of reflections 498471 35393
No. of reflections (Rfree) 25178 1754
R.m.s.d., bonds (A˚) 0.008 0.008
R.m.s.d., angles () 1.45 1.31
No. of protein atoms 2787 2671
No. of NADP+ atoms 48 48
No. of JF0064 atoms 22 22
No. of solvent molecules 705 174
Ramachandran plot, residues in (%)
Favoured regions 98.60 98.77
Allowed regions 1.40 1.23
PDB entry 4igs 4icc
† Anomalous pairs were treated separately.
K125R mutation, after the failure of the previous method, a
different strategy was used. Two non-overlapping primers
were designed covering the AKR1B10 cDNA region from
base pairs 393 to 432: TGGGAAAAGGTCATCCCCA
(reverse complement; base pairs 393–412) and GAGATGA-
TAAAGGTAATGCCAT (forward; base pairs 413–434).
Mutated nucleotides are shown in bold. After the PCR reac-
tion, phosphorylation and ligation were carried out. The
ligation product was incubated with DpnI (New England
Biolabs) at 37C for 60 min to ensure the digestion of the
Dam-methylated parental strand. The K125R/V301L double
mutant was prepared with pET30-Xa/LIC-AKR1B10 V301L
as a template using the same methodology as for the K125R
mutation. Finally, in all cases, the resulting nicked circular
mutagenic strands were transformed into Escherichia coli
DH5 and the plasmids were sequenced by GATC Biotech.
The cDNAs of AR and AKR1A1 were cloned into the
pET15b plasmid and that of AKR1B10 into the pET16b
plasmid (pET30-Xa/LIC was used for the K125R/V301L
mutant). AR, wild-type and mutant AKR1B10, and AKR1A1
were recombinantly expressed in the E. coli BL21(DE3) strain
(Novagen) and were purified using the procedures described
previously for AR (Lamour et al., 1999), AKR1B10 (Gallego
et al., 2007) and AKR1A1 (Barski et al., 1995). Purity was
confirmed by SDS–PAGE and protein concentrations were
determined using a NanoDrop ND-1000 (Thermo Scientific).
2.2. Inhibition screening
The IC50 activity assays were carried out according to a
previously described method (de la Fuente et al., 2003) based
on the spectrophotometric quantification of NADPH ("340 =
6220 M1 cm1) consumption, which takes place when the
enzyme catalyzes the reduction of d,l-glyceraldehyde. The
assays were performed in 96-well microtitre plates at 25C in
100 mM sodium phosphate buffer pH 7.0 with recombinant
protein (AR and AKR1B10), a substrate concentration of
about 10  Km and 0.2 mM NADPH. The final reaction
volume was 200 ml per well. The compounds assayed were
dissolved in dimethyl sulfoxide (DMSO) and the corre-
sponding solution was added to the well and pre-incubated
for 5 min at 25C prior to addition of the substrate. The final
DMSO concentration in the well was 5%(v/v). The reaction
was initiated by the addition of 1, 60 and 5 mM glyceraldehyde
(for AR, AKR1B10 and AKR1A1, respectively) and the
decrease in optical density at 340 nm was monitored for 5 min
at 25C in a microtitre plate reader (Wallace 1420 VICTOR3,
Perkin Elmer). The IC50 value for each test compound was
determined as the compound concentration that inhibits
enzymatic activity by 50%. The IC50 was calculated using the
GraFit program (v.5.0; Erithacus Software) and values were
given as the mean  standard deviation of three experiments.
2.3. Determination of Ki values
The inhibition pattern and Ki values were determined by
using six different concentrations of d,l-glyceraldehyde as a
substrate and three concentrations of JF0064 inhibitor: 0.3, 0.6
and 1.8 mM for AR and 0.5, 1 and 3 mM for AKR1B10. The
enzymatic activity was monitored by the change in NADPH
concentration (absorbance at 340 nm) at 25C in a UV–visible
spectrophotometer (Cary 400 Bio, Varian) using a reaction
mixture containing 0.1 M sodium phosphate pH 7.4 and
0.5 mM NADPH. The final concentration of carrier solvent,
DMSO, was 5%(v/v). One unit (U) of activity corresponds to
the transformation of 1 mmol substrate per minute. The kinetic
constants were calculated by fitting the initial rates to the
appropriate equation using GraFit (v.5.0; Eritacus Software).
The Ki values are expressed as the mean  standard deviation
of three independent determinations.
2.4. Crystallization and structure determination
Regarding the AR–NADP+–JF0064 complex, crystals could
not be obtained by co-crystallization. Therefore, an initial
soaking trial with crystals of native AR–NADP+ obtained
under the published conditions (50 mM ammonium citrate pH
5.0, 20% polyethylene glycol, PEG 6000) was performed with
10 mM JF0064 for 6 d at 24C without success. To avoid
interference with the citrate used during crystallization, the
ammonium citrate was replaced by MES. Crystals of native
AR–NADP+ were obtained in 50 mM MES pH 5.5, 20 mM
ammonium sulfate, 20% PEG 6000 by the hanging-drop
vapour-diffusion method at 24C. With the aim of obtaining
electron density for JF0064, a second trial of soaking was
performed on these crystals with 4 mM JF0064 for 6 d at 24C.
Cryocooling in liquid nitrogen was carried out using a cryo-
protecting solution containing 40% PEG 6000. Data collection
was performed to 0.85 A˚ resolution on the X06SA beamline at
the Swiss Light Source. The crystals belonged to space group
P21, with one protein molecule in the asymmetric unit. Data
were processed with HKL-2000 (Otwinowski & Minor, 1997).
Data-collection statistics are listed in Table 1.
Regarding the AKR1B10–NADP+–JF0064 complex,
reductive methylation of lysine residues was performed to
improve the crystal packing. The method used is derived from
that published previously (Rayment, 1997; Rayment et al.,
1993). After protein purification, the methylation reaction was
performed overnight in 50 mM HEPES pH 8.0 at a protein
concentration of 1 mg ml1. 50 ml freshly prepared 1 M
dimethylamine–borane complex (Sigma–Aldrich) and 80 ml
1 M formaldehyde were added per millitre of protein solution
and incubated at 4C for 16 h. Methylation was stopped by the
addition of 25 mM Tris–HCl pH 8.0. Prior to crystallization,
methylated AKR1B10 (mAKR1B10) was dialyzed against
20 mM NaCl, 25 mM Tris pH 8.0, 40 mM HEPES pH 8.0,
concentrated to 30 mg ml1 and then mixed with a solution of
NADP+ to achieve a 1:4 molar ratio of AKR1B10:NADP+. For
the co-crystallization with JF0064, a 4 mM inhibitor concen-
tration was used. Crystals of the complex were obtained by the
hanging-drop vapour-diffusion method at 24C. The protein
solution was mixed with an equal volume of precipitating
solution consisting of 100 mM sodium cacodylate pH 9.0, 30%
PEG 6000 and equilibrated against 500 ml of the precipitating
solution. The same crystallization conditions were used for
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wild-type mAKR1B10 and the mAKR1B10 K125R and
mAKR1B10 K125R/V301L mutants. Cryocooling in liquid
nitrogen was carried out using a cryoprotecting solution
containing 40% PEG 6000. X-ray data for mAKR1B10
K125R/V301L–NADP+–JF0064 were collected on the home
laboratory X-ray source to 1.75 A˚ resolution. The data were
processed with HKL-2000 (Otwinowski &Minor, 1997). Data-
collection statistics are listed in Table 1.
2.5. Structural refinement
The atomic coordinates of the human AR–NADP+–
IDD594 complex (PDB entry 1us0; Howard et al., 2004), which
is the highest resolution AR structure available, were used to
solve the structure of the AR ternary complex, while those of
AKR1B10–NADP+–tolrestat (PDB entry 1zua; Gallego et al.,
2007) were used for AKR1B10. In both cases, molecular
replacement was performed with AMoRe (Navaza, 2001).
Crystallographic refinement involved repeated cycles of
conjugate-gradient energy minimization and temperature-
factor refinement performed with REFMAC5 (Murshudov et
al., 2011) and PHENIX (Adams et al., 2010). The JF0064 PDB
file was built using ChemDraw (Perkin Elmer) to generate a
two-dimensional formula and was refined with ChemBio3D
(Perkin Elmer) to add the stereochemistry and with Open
Babel (O’Boyle et al., 2011) for conversion to PDB format.
The restraint dictionary (libcif format) was then written with
REFMAC5 based on the PDB and mtz files, with standard
stereochemistry. Amino-acid side chains and water molecules
were fitted into 2Fo  Fc and Fo  Fc electron-density maps
with Coot (Emsley et al., 2010). The final Fo  Fc map indi-
cated clear electron density for JF0064 in both complexes.
Refinement statistics are presented in Table 1. The atomic
coordinates have been deposited in the PDB (entries 4igs and
4icc) and will be released immediately upon publication.
Finally, in order to perform a more complete study regarding
the fine geometric details of the ultrahigh-resolution AR–
NADP+–JF0064 structure, the SHELXL program (Sheldrick,
2008) was used. A .lst file corresponding to JF0064 distances
and angles is included within the Supporting Information1.
Related figures were prepared with PyMOL (v.1.3; Schro¨-
dinger).
2.6. Molecular dynamics
The molecular-dynamics (MD) simulations of AKR1B10–
NADP+–JF0064 were performed using Amber12 and the
SPFP precision model (Le Grand et al., 2013). Analysis of the
trajectory was carried out using ptraj and cpptraj (Roe &
Cheatham, 2013) as implemented in AmberTools12 (Case et
al., 2012; Salomon-Ferrer et al., 2013). Molecular preparation
of the AKR1B10 holoenzyme–JF0064 complexes was carried
research papers
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Table 2
IC50 values of the JF inhibitor series against AR and AKR1B10.
IC50 (mM) IC50 ratio
Compound AR AKR1B10 AKR1B10/AR
1† 6.4  1.1‡ — —
2† 25%‡ — —
3† 0%‡ — —
JF0021 3.2  1.1 32  4 10
JF0025 (15†) 5.7  1.6 2.3  0.2 0.4
JF0042 (24†) 8.9  4.2 >55 >6.2
JF0053 (27†) 4.4  2.5 3.4  0.5 0.8
JF0064 0.3  0.1 1.0  0.1 3.4
JF0127 3.7  1.6 1.6  0.2 0.4
JF0143 6.5  4.5 1.8  0.2 0.3
JF0246 (13†) >46 >200 —
† Compounds named as in de la Fuente et al. (2003). ‡ Data taken from de la Fuente et
al. (2003): IC50 value or percentage of inhibition at 25 mg ml
1 compound.
Figure 2
Inhibitory effect of JF0064 on the glyceraldehyde reductase activity of
AR and AKR1B10. (a) Lineweaver–Burk plot showing the effect on the
reduction of d,l-glyceraldehyde by AR at different JF0064 concentra-
tions: 0 (empty circles), 0.3 mM (filled circles), 0.6 mM (empty squares)
and 1.8 mM (filled squares). (b) Lineweaver–Burk plot showing the effect
on the reduction of d,l-glyceraldehyde by AKR1B10 at different JF0064
concentrations: 0 (empty circles), 0.5 mM (filled circles), 1 mM (empty
squares) and 3 mM (filled squares). Abbreviations: U, units (mmol min1),
Vo, initial rate. Data fitting and plots were performed with GraFit (v.5.0;
Erithacus Software).
1 Supporting information has been deposited in the IUCr electronic archive
(Reference: RR5047).
out using MOE (v.2012.10; Chemical Computing Group,
Montreal, Canada; http://www.chemcomp.com). The input
structures of the protein and the ligand were prepared from
the mAKR1B10 K125R/V301L–NADP+–JF0064 structure
reported here; for the wild-type structure residues Arg125 and
Leu301 were mutated to Lys125 and Val301 in silico using
MOE. For AKR1B10 and AKR1B10 K125R/V301L, each in
complex with JF0064, 110 ns MD simulations were carried out
(for the ligand with protonated hydroxyl groups and the ligand
containing the deprotonated hydroxyl group at position 4).
Further details of the procedure are included in the
Supporting Information. Related figures were prepared with
PyMOL (v.1.3; Schro¨dinger).
3. Results
3.1. Determination of the selectivity of the JF inhibitor series
for AR and AKR1B10
In a previous study, de la Fuente et al. (2003) discovered a
polybrominated diaryl ether in a marine sponge (compound 1
in Fig. 1b) which was found to inhibit recombinant human
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Figure 3
General view of the X-ray structures of the AR–NADP+–JF0064 and mAKR1B10 K125R/V301L–NADP+–JF0064 complexes. (a) Superposition of the
AR–JF0064 and mAKR1B10–JF0064 complexes with the protein main chain represented as cartoon loops (AR, marine blue; mAKR1B10, olive green)
and the cofactor NADP+ (orange) and JF0064 as sticks (AR, cyan; mAKR1B10, green). External loops are highlighted and an enlargement of the JF0064
binding site is shown inside the square. (b, c) JF0064 complexed with AR (b) or mAKR1B10 K125R/V301L (c) holoenzyme in a surface representation
coloured according to the local electrostatic potential (blue, positive charge; white, neutral; red, negative charge) calculated with PyMOL.
AR with an IC50 value of 6.4 mM. Two other natural poly-
brominated diaryl ethers (compounds 2 and 3 in Fig. 1b)
isolated from the same species and closely related to 1 were
also assayed. Thus, a series of polyhalogenated analogues
(Fig. 1b) were synthesized and tested in vitro to explore the
structure–activity relationship (SAR) and displayed various
degrees of inhibitory activity (de la Fuente et al., 2003). In
the present study, four of these compounds and four other
unpublished polyhalogenated derivatives were analyzed with
respect to their IC50 values against AR and AKR1B10 to
find new and selective inhibitors of these enzymes (Fig. 1b,
Table 2). JF0064 was detected to be the most potent
compound with both AR and AKR1B10 (IC50 for AR = 0.3 
0.1 mM; IC50 for AKR1B10 = 1.0  0.1 mM). In order to assess
the selectivity of JF0064 in comparison to AKR1A1, we
determined its IC50 against the latter enzyme. The value
obtained was 7.4  0.6 mM, which represents about 25-fold
and sevenfold selectivity for AR and AKR1B10, respectively.
3.2. Determination of the Ki values of the novel type of ARI
JF0064
Once the IC50 assays had revealed a new lead among the
screened compounds, determination of the Ki value and the
inhibition mechanism was performed for JF0064. This
compound represents a novel inhibitor chemical class, as it
contains neither the carboxylic acid nor the cyclic imide
moiety incorporated in most ARIs and AKR1B10 inhibitors.
In general, these inhibitors display a characteristic non-
competitive inhibition pattern against the substrate (Barski et
al., 2008; Bohren & Grimshaw, 2000; Verma et al., 2008).
For the determination of Ki values, d,l-glyceraldehyde was
used as a substrate with both AR and AKR1B10. JF0064
inhibition followed a non-competitive pattern with both
enzymes (Fig. 2), showing values of 0.54 and 1.7 mM for AR
and AKR1B10, respectively. Consequently, although JF0064
belongs to a novel ARI/AKR1B10 inhibitor chemical class, it
is likely to follow the same inhibition mechanism. These data
suggest an acidic character of the tetrafluorophenol moiety in
JF0064, similar to that of cyclic imides, i.e. the inhibitor is
transported as a neutral molecule and becomes negatively
charged when binding to the target enzyme.
3.3. Structure determination of AR and AKR1B10 complexes
with JF0064 by X-ray crystallography
Following the IC50 assays, JF0064 was selected for protein
crystallization trials with both AR and AKR1B10 with the
purpose of finding (i) the structural basis of the inhibition
properties of this new scaffold and (ii) some hints for
increasing its potency and selectivity.
Regarding the AR–NADP+–JF0064 complex, crystals could
not be obtained by co-crystallization. A first soaking trial was
performed with crystals of native AR–NADP+ obtained under
the published conditions (Lamour et al., 1999) in ammonium
citrate buffer pH 5.0. The X-ray structure obtained displayed
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Figure 4
Inhibitor-binding site of AR/AKR1B10–JF0064 complexes. (a) Atomic representation of the inhibitor-binding site for the AR–NADP+–JF0064 complex,
with the inhibitor electron density shown as a A-weighted 2Fo  Fc map contoured at the 2 level. Water molecules HOH-95, HOH-194 and HOH-245
(not shown for clarity) are hydrogen bonded to the JF0064 outer hydroxyl group. (b) Atomic representation of the inhibitor-binding site for the
mAKR1B10 K125R/V301L–NADP+–JF0064 complex with the inhibitor electron density shown as a A-weighted 2Fo  Fc map contoured at the 1
level. Protein main chain is represented with white cartoon loops and key residues forming the JF0064-binding site are displayed as sticks, while the
inhibitor is shown in ball-and-stick representation. The mutated Leu301 is identified with a label in italics. The colour code is as in Fig. 3, water molecules
are represented as red spheres and labels are in the corresponding colours. Distances are indicated in A˚ for hydrogen-bonded atoms.
low-quality electron density for the JF0064 molecule (data not
shown). Citrate is an uncompetitive inhibitor of AR, and the
X-ray structure of the native crystals showed two citrate
molecules bound in the active site of the protein (Biadene
et al., 2007; Harrison et al., 1994), which could potentially
hamper JF0064 binding. Since pig AR had been crystallized in
the presence of MES buffer pH 6.2, we used this buffer instead
of ammonium citrate (Calderone et al., 2000; Urzhumtsev et
al., 1997). Crystals of native AR–NADP+ obtained in 50 mM
MES pH 5.5 were used for a second trial of soaking with
compound JF0064. The X-ray structure was determined at
0.85 A˚ resolution and refined to a final Rwork of 13.48% and
Rfree of 14.33%. The structure of the complex was determined
in space group P21, which is the most commonly observed for
AR crystals. There was one monomer in the asymmetric unit,
with a calculated solvent content of 44.00% and a Matthews
coefficient of 2.20 A˚3 Da1. Table 1 shows the data-collection
and refinement statistics.
Regarding AKR1B10, holoenzyme or ternary-complex
crystals could not be obtained using the wild-type or several
mutant proteins, including active-site and surface mutants.
Attempts failed under the published conditions and with
robotic crystallization screens, except for tolrestat-containing
complexes. Indeed, crystals of AKR1B10–NADP+–tolrestat
and of AKR1B10 V301L–NADP+–tolrestat complexes were
obtained.
Several studies have demonstrated that methylation of the
solvent-exposed "-amino group of lysine residues changes the
properties of the protein and may promote crystallization via
improvement of crystal packing (Sledz et al., 2010; Walter
et al., 2006). Therefore, reductive methylation of wild-type
AKR1B10 was assayed prior to crystallization trials. Crystals
of methylated AKR1B10 (mAKR1B10) holoenzyme were
obtained under the conditions previously published for the
AKR1B10–NADP+–tolrestat complex (Gallego et al., 2007),
and its X-ray structure revealed that Lys125 in loop A was
monomethylated (data not shown). Thus, with the aim of
retaining the positive charge, this residue was mutated to
arginine. Co-crystals were obtained using the mAKR1B10
K125R–NADP+–JF0064 complex, but they did not show
electron density corresponding to the bound ligand (data not
shown). However, when including the V301L mutation, the
X-ray structure of an mAKR1B10 K125R/V301L–NADP+–
JF0064 complex co-crystal was obtained at 1.75 A˚ resolution
and refined to a final Rwork of 16.20% and Rfree of 18.64%. The
structure of the complex was determined in space group P31.
There was one monomer in the asymmetric unit, with a
calculated solvent content of 50.67% and a Matthews coeffi-
cient of 2.49 A˚3 Da1. Table 1 shows the data-collection and
refinement statistics.
Prior to crystallization trials of wild-type and mutant forms
of mAKR1B10, they were tested for activity using an enzy-
matic assay. In all cases, the specific activity of the mAKR1B10
forms was the same as that of wild-type AKR1B10
(0.8 mmol min1 mg1 with glyceraldehyde, as reported
previously; Gallego et al., 2006), ensuring that the methylated
proteins kept their functionality. JF0064 IC50 assays were also
performed with AKR1B10 K125R/V301L and mAKR1B10
K125R/V301L, showing very similar values (7  1.7 and 8.2 
1.1 mM, respectively) and ensuring that the methylated protein
behaved similarly in inhibition assays.
3.4. Structure overview and inhibitor-binding site of the
AR/AKR1B10–NADP+–JF0064 complexes
The X-ray structures of both complexes revealed an (/)8
barrel characteristic of the proteins of the AKR superfamily.
The NADP+ is bound in an extended conformation adjacent to
the active site located at the C-terminal end of the barrel, with
the inhibitor JF0064 positioned between the external loops B
and C. JF0064 is a symmetrical molecule composed of two
identical phenol rings linked by a single C—C bond. Each ring
contains four F atoms in the ortho and meta positions and the
hydroxyl group in the para position (Figs. 1b and 1c). In the
enzyme–inhibitor complexes, one of the rings (the ‘inner ring’)
is bound to the anion-binding pocket, while the other ring (the
‘outer ring’) points towards the solvent and is near loops B and
C (Fig. 3). Comparison of the binding modes of JF0064
between AR and AKR1B10 shows that while the inner ring is
similarly placed but slightly rotated, the outer ring is signifi-
cantly displaced (Fig. 3a). In this regard, it is noteworthy that
while the binding of JF0064 does not open the specificity
pocket in either of the two structures, there are some differ-
ences between the two active-site binding pockets given by the
different positioning of the three external loops (Fig. 3).
The analysis of interactions between the AR holoenzyme
and JF0064 (Figs. 4a and 5) shows that catalytic residues Tyr48
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Figure 5
Detail of the inhibitor-binding site of the AR–NADP+–JF0064 complex
at ultrahigh resolution: side view of an atomic model of JF0064 in cyan
ball-and-stick representation with the AR interacting residues Tyr48,
His110 and Trp111 shown as marine blue sticks. H atoms of these residues
which are involved in hydrogen bonds are displayed in sticks and their
electron densities are shown as A-weighted Fo  Fc maps contoured at
the 1.5 level in green. The length of the C—O bond of each phenol
moiety of JF0064 is indicated.
and His110 establish hydrogen bonds to the O atom of the
hydroxyl group of the inner ring (2.60 and 2.67 A˚, respec-
tively) and define the prototypical anion-binding pocket
observed in the AR–ARI complexes. Moreover, this hydroxyl
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Figure 6
Molecular-dynamics (MD) simulation of the AKR1B10 wild-type holoenzyme complex with JF0064 and comparison with the mAKR1B10 mutant and
AR crystallographic structures. The presented MD frame was derived from clustering of the second 110 ns MD run of this protein complex. The shown
cluster is populated with 5849 frames (53.2% of this MD run). (a) Atomic representation of the inhibitor-binding site for the complex of the wild-type
AKR1B10 holoenzyme with JF0064. Protein main chain is represented by white cartoon loops and key residues forming the JF0064-binding site are
displayed as violet sticks, while the inhibitor is shown in pink ball-and-stick representation and the cofactor in shown as orange sticks. (b) Atomic
representation of the inhibitor-binding site residues of the mAKR1B10 K125R/V301L–NADP+–JF0064 complex (olive green sticks) superimposed onto
the AKR1B10–NADP+–JF0064 complex (violet sticks). Inhibitor molecules are shown as thinner green and pink sticks. Residue labels are shown in
black, except for the case of the mutated residue Leu301, where they are shown in olive green italics. (c) Atomic representation of the inhibitor-binding
site residues of the AKR1B10–NADP+–JF0064 complex (violet sticks) superimposed onto AR–NADP+–JF0064 (blue sticks). Inhibitor molecules are
shown as thinner pink and cyan sticks. Residue labels are in violet for AKR1B10 and in blue for AR. (d) JF0064 (pink ball-and-stick representation)
complexed with AKR1B10 holoenzyme in a surface representation coloured according to the local electrostatic potential (blue, positive charge; white,
neutral; red, negative charge) calculated with PyMOL.
group seems to be negatively charged, which is supported by
two different observations. Firstly, its observed C—O bond
distance is 1.3229  0.0124 A˚ (obtained by an unrestrained
refinement with SHELXL; Supporting Information), which is
significantly shorter than the C—OH bond distance reported
as 1.36 A˚ (Prince et al., 2006). On the contrary, the distal ring
hydroxyl group presents a C—O bond distance of 1.3528 
0.0189 A˚ (obtained by an unrestrained refinement with
SHELXL; Supporting Information), indicating that it is not
charged. The second observation supporting the negative
charge of the inner ring hydroxyl group is the observation of
difference map peaks corresponding to the H atoms bonded to
the OH of Tyr48 and the N"2 atom of His110 (green contours
in Fig. 5). The H atom of the distal ring hydroxyl group of
JF0064 is not observed in the difference map (at the same
contour level as for the inner ring hydroxyl), possibly because
this hydroxyl is exposed to the solvent. Trp111 forms a
hydrogen bond to the F3 atom (2.93 A˚; Figs. 4a and 5) and also
makes a hydrophobic contact with the inner ring, along with
Trp20 and the nicotinamide ring of the cofactor. The outer ring
interacts through hydrophobic contacts with Trp219, Leu300
and Cys298, and with a hydrogen-bond network involving its
hydroxyl group, water molecules HOH-71, HOH-95, HOH-
194 and the main-chain N atoms of residues Ala299, Leu301
and Ser302 (and the side-chain O atom of Ser302). HOH-245
also interacts with the hydroxyl of the outer ring and other
water molecules, but it is not bonded to the protein. Moreover,
an additional hydrogen bond is formed between the N atom
of the main chain of Leu300 and the F30 atom. All of these
contacts and their corresponding distances can be observed in
Fig. 4(a).
The analysis of the interactions between the mAKR1B10
K125R/V301L holoenzyme and JF0064 (Fig. 4b) shows that,
analogously to its AR counterpart, the catalytic residues Tyr49
and His111 establish hydrogen bonds to the acidic hydroxyl of
JF0064 (2.64 and 2.59 A˚, respectively), while Trp112 interacts
with F3 (2.84 A˚). Trp21, Trp112 and the nicotinamide moiety
of NADP+ also make hydrophobic interactions with the
inhibitor inner ring. In contrast, the side-chain N"1 atom of
Trp21 in the B conformation (40% occupancy) forms a
hydrogen bond to F20 (3.21 A˚). Regarding the outer ring, the
hydroxyl group of the inhibitor interacts through hydrogen
bonds with the N"1 atom of Trp220 and HOH-143. This water
molecule, in turn, extends the hydrogen-bond network to the
carbonyl O atom of Ala298 and to the main-chain N atom of
Asn300. Finally, the F50 atom is hydrogen-bonded to the main-
chain N atom of Leu301 (2.86 A˚). All of these contacts and
their corresponding distances can be observed in Fig. 4(b).
3.5. Molecular dynamics and inhibitor-binding site of
wild-type AKR1B10
As the structure of wild-type AKR1B10 holoenzyme
complexed with JF0064 could not be determined, we decided
to perform molecular dynamics (MD) in order to simulate the
inhibitor-binding pose based on the crystal structure of
mAKR1B10 K125R/V301L. Regarding the AKR1B10 wild-
type complex, MD could only achieve a binding geometry of
the ligand that closely approaches the state in the crystal
structure when the ligand was deprotonated at the inner
hydroxyl group. In this case, we obtained an r.m.s.d. value
close to 1 A˚ from the crystal structure (see the r.m.s.d. plots in
the Supporting Information). In the case in which the inner
hydroxyl group had been protonated, we only obtained
r.m.s.d.s of around 2 A˚ or higher (data not shown). On the
other hand, the outer tetrafluorophenol moiety is more flex-
ible as it is more strongly exposed to the solvent and to flexible
external loops. The inhibitor-binding site in the wild-type
protein is similar to that in the crystal structure for the inner
tetrafluorophenol moiety. The previously described main
contacts between JF0064 and residues Tyr49, His111 and
Trp112 remain conserved (Fig. 6a). Superimposition of the
X-ray structure and a representative MD pose (see Supporting
Information) shows that the most significant change is indeed
the replacement of Leu301 by Val (Arg125 is located far from
the pocket and should not be involved in JF0064 binding).
Val301 cannot provide a proper stacking with Trp112 as does
Leu; accordingly, Val301 is quite mobile. The flexibility of
Val301 allows Gln303 to shift closer to the inhibitor, while the
upper ring of JF0064 can approach closer to loop C (Fig. 6b).
These movements finally allow the formation of a hydrogen
bond between the outer hydroxyl and the N atom of the amide
of Gln303, a direct interaction that is not observed in the
X-ray mAKR1B10 mutant structure (Figs. 4b and 6b). This
is consistent with a lower IC50 value for wild-type AKR1B10
(1.0 mM versus 8.2 mM for the mutant).
4. Discussion
4.1. Structural basis for the inhibitory potency and selectivity
of the JF0064 lead compound
While nearly 100 X-ray structures of AR have been
deposited in the PDB, only two structures had been released
for AKR1B10 prior to the submission of this publication
(during the revision procedure, a study including four new
AKR1B10 X-ray structures was published; Zhang et al., 2013):
(i) a ternary complex with tolrestat (PDB entry 1zua; Gallego
et al., 2007) and (ii) a ternary complex with fidarestat (PDB
entry 4gab; recently solved in our laboratory by replacement
soaking; Ruiz et al., 2013). This reflects the intrinsic difficulties
in obtaining crystals of AKR1B10–ligand complexes.
The majority of methods used to overcome these difficulties
are focused on changing the crystallization conditions.
However, the properties of the protein molecule also strongly
influence the crystallization process. Thus, an alternative
approach is to modify the macromolecule rather than the
crystallization conditions. The surface lysine methylation
(SLM) technique provides such a modification and can
improve the rate of success of protein crystallization by
chemically methylating lysine residues. SLM promotes crys-
tallization as the methylation of the solvent-exposed "-amino
group of lysines changes some of the protein properties (pI,
solubility and hydropathy) and decreases the surface entropy
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(Kim et al., 2008; Sledz et al., 2010; Walter et al., 2006). In the
present work, SLM allowed co-crystals to be obtained after
numerous trials of crystallization conditions with the wild-type
and mutant proteins.
In addition to SLM, two amino-acid mutations were intro-
duced. The first one was the replacement of Lys125 by an Arg
residue. This lysine is monomethylated after SLM; however,
Lys125 is in a key position and therefore could presumably be
involved in interactions with some of the inhibitors (Table 3;
Endo, Matsunaga, Kuwata et al., 2010; Endo et al., 2009;
Matsunaga et al., 2009; Soda, Hu et al., 2012; Takemura et al.,
2011; Zhao et al., 2010) and probably in the loop A confor-
mation. Indeed, the most mobile region in the AKR1B10
holoenzyme complex with tolrestat was loop A, extending
from Lys125 to Ala131 (Gallego et al., 2007). Therefore, in
order to keep the positive charge, this lysine was mutated to
arginine. The other mutation was the exchange of Val301 to
Leu (the corresponding residue in AR). In fact, co-crystal
preparation was attempted with mAKR1B10 K125R–JF0064,
but no electron density could be observed for the ligand. As
we reported previously in the case of the AKR1B10 V301L–
NADP+–fidarestat complex (Ruiz et al., 2013), the mutation of
Val301 to Leu is an essential prerequisite for the observation
of JF0064 by X-ray crystallography. While in the complex with
fidarestat this fact can be explained by the stronger binding of
the inhibitor, in the present case it is not very evident (it could
be linked to loop A rearrangement originating from the
V301L mutation).
A structural biology highlight of the present work is the
ultrahigh resolution (1 A˚ or better; Lecomte et al., 2008) of the
AR–NADP+–JF0064 ternary complex, which was determined
at 0.85 A˚. At such resolution, the level of detail observed in
the best-ordered areas approaches that in small-molecule
studies. H atoms and bond densities are clearly visible and
estimation of the atomic charges starts to be possible
(Podjarny et al., 2004). In this sense, the ultrahigh resolution
has unveiled some important structural and biochemical
details regarding the interaction of JF0064 with AR and its
inhibition. The most remarkable observation is the evidence
that JF0064 is negatively charged. Firstly, the observed C—O
bond distance of the hydroxyl group of the inner ring (1.32 A˚)
fits that of a charged hydroxyl group, while in the case of the
hydroxyl group of the distal ring (1.35 A˚) it matches a non-
charged group better. Interestingly, Gregson and coworkers
have obtained the three-dimensional structure of meso-
5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane:
4,40-biphenol (1:2 molar ratio), a salt containing both neutral
and anionic biphenol units (Gregson et al., 2000). They
observed that the distances for the two uncharged C—OH
bonds were 1.358 and 1.360 A˚, whereas in the case of the
charged C—O bond the distance was 1.337 A˚; a change in the
same direction is observed in this work. Secondly, it is possible
to observe the H atoms of the hydrogen-bonded residues
Tyr48 and His110 in the difference maps (Fig. 5). Indeed,
Costantino et al. (1999) measured the pKa values of some of
the benzopyran-4-one derivatives that have been assayed as
ARIs. In their study, the benzopyran derivative with a
7-hydroxyl group exhibited a pKa value of 7.3, approaching
the pH of the enzymatic assay and thus being partially in an
anionic form. Conversely, the benzopyran derivative bearing
a 7-methoxy substituent, in which proton dissociation was
prevented, was found to be much less active. In our case, the
electron-withdrawing F substituents confer a negative induc-
tive effect, increasing the acidic character of the JF0064
hydroxyl groups. In fact, it has been reported that the pKa
value of 2,3,5,6-tetrafluorophenol is 5.53 (Kipper et al., 2011).
Note also that the short distance between the O atoms of the
inner hydroxyl group of the inhibitor and Tyr48 (2.61 A˚), in
addition to the position of the H atom, which is clearly next to
the tyrosine residue, indicates that this bond is likely to be a
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Table 3
Hydrogen-bond interactions of inhibitors containing hydroxyl groups in the active site of AR/AKR1B10.
All the interactions were predicted from computer docking simulations, with the exception of those of JF0064 in aldose reductase and the same inhibitor with
residues Tyr49 and His111 in AKR1B10.
Residues in hydrogen-bond interactions (chemical groups involved)
Inhibitor Anion-binding pocket Specificity pocket† Reference
AR
JF0064 Tyr48/His110 (hydroxyl) No interaction Present work
Benzopyran-4-one derivatives Tyr48/His110 (hydroxyl) Thr113 (hydroxyl) Costantino et al. (1999), Rastelli et al. (2000)
Chalcone derivative Tyr48/His110 (hydroxyl) Thr113 (hydroxyl) Rastelli et al. (2000)
AKR1B10
JF0064 Tyr49/His111 (hydroxyl) Gln303 (hydroxyl) Present work
Caffeic acid‡ Tyr49/His111 (hydroxyl) Gln114 (hydroxyl) Soda, Hu et al. (2012)
Mangostin His111 (hydroxyl) Gln303 (hydroxyl) Soda, Endo et al. (2012)
Isolithocholic acid Tyr49/His111 (hydroxyl) Lys125/Gln303 (carboxyl) Endo et al. (2009)
Bisdemethoxycurcumin Tyr49/His111 (hydroxyl) Gln114/Ser304 (hydroxyl) Matsunaga et al. (2009)
Oleanolic acid Tyr49/His111 (hydroxyl) Gln303 (carboxyl) Takemura et al. (2011)
MTF§ Trp21/His111 (hydroxyl/carbonyl) Lys125/Gln303 (hydroxyl) Zhao et al. (2010)
Glycyrrhetic acid Tyr49/His111 (hydroxyl) Lys125 (carboxyl) Endo, Matsunaga, Soda et al. (2010)
Ursolic acid Tyr49 (hydroxyl) Lys125 (carboxyl) Takemura et al. (2011)
† The listed interactions mostly open the specificity pocket. When this does not happen, the residues interacting with the inhibitor indicated here are outside the anion-binding
pocket. ‡ Caffeic acid phenethyl ester (CAPE)-based inhibitor: 3-(4-hydroxy-2-methoxyphenyl)acrylic acid 3-(3-hydroxyphenyl)propyl ester. § 9-Methyl-2,3,7-trihydroxy-6-
fluorone.
short ionic hydrogen bond (Fuhrmann et al., 2006), in agree-
ment with the electrostatic character of the binding of JF0064
to the anionic site. In the corresponding AKR1B10 complex,
the hydrogen-bond distances between Tyr49 OH and
His111 N"1 and the JF0064 hydroxyl group (2.64 and 2.59 A˚,
respectively) also agree with the proposed acidic character
of the latter hydroxyl group. The lower resolution of the
AKR1B10 complex (1.75 A˚) does not allow the observation of
any H atoms. However, as the inhibition pattern observed for
JF0064 with both enzymes is equivalent, it is reasonable to
expect that this hydroxyl group will also possess an acidic
character in the latter case. Moreover, MD simulations with
wild-type AKR1B10 holoenzyme complexed with JF0064 also
support our observation. If Tyr50/49 is protonated (as has
been observed for the AR–NADP+–JF0064 complex), this
analysis suggests that the inner hydroxyl group is deproton-
ated.
The second important point concerns the hydrogen bonds
involving organic F atoms. This is a subject which has been
discussed with some controversy (Dunitz, 2004); however,
hydrogen bonds of the C—F  H—N or C—F  H—O types
have been described previously for AR and AKR1C3 inhibi-
tors (Lovering et al., 2004; Rastelli et al., 2002). In fact, the
ultrahigh-resolution difference map shows a peak corre-
sponding to the H atom of N"1 of Trp111 directed towards
F3 of JF0064 (Fig. 5), confirming the hydrogen bond to the F
atom.
The MD simulations allowed us to obtain a model of the
AKR1B10 holoenzyme complexed with JF0064. The super-
position of this model with the AR cognate complex shows
JF0064 to be nearly identically placed in both enzymes
(Fig. 6c), with even the outer moiety (displaced towards loop
B in the crystallized mAKR1B10 mutant; Fig. 3a) and the
contacts with the outer hydroxyl group being similar.
However, there is a difference which might account for the
threefold difference in the IC50 values: the displacement of
Phe122/Phe123. In AR, Phe122 is oriented towards the active
site and seals the pocket more efficiently than Phe123 in
AKR1B10, which points towards the solvent and exhibits a
more open pocket (Fig. 6d). In fact, the MD suggested a
subpocket next to loop A (including Phe123) which appears
to be more loosely packed than in AR. The pocket accom-
modated a buried water molecule trapped inside it (data not
shown), a process usually linked to an entropic penalty, as
previously observed in the complex of AKR1B10 V301L with
fidarestat (Ruiz et al., 2013).
In summary, it can be concluded that for both AR and
AKR1B10 the strong interaction with the anion-binding
pocket accomplished by inhibitors with a carboxylic acid or a
cyclic imide group (Bohren & Grimshaw, 2000) is matched by
the binding of the acidic hydroxyl moiety of JF0064 in a non-
competitive mode.
4.2. Perspectives of the JF0064 compound for drug design
JF0064 has emerged as a new lead compound targeting
AR/AKR1B10. Previously, some compounds have been
characterized as novel ARI/AKR1B10 inhibitors, and
molecular-docking studies predicted hydrogen bonding to the
anion-binding pocket via hydroxyl groups (Fig. 1a and Table
3). Similarly to JF0064, the inner hydroxyl group of these
compounds is within hydrogen-bonding distance of the active-
site catalytic Tyr or His residue. The distal hydroxyl (or
carboxyl) group seems to interact with hydrophilic residues
of loops A and C (except for AR and JF0064, in which the
interaction is mediated by a network of ordered water mole-
cules). Here, we show for the first time X-ray structures of AR/
AKR1B10 complexed with an inhibitor exhibiting a substi-
tuted phenol moiety, which could be a good bioisosteric group
for replacing the carboxylic acid (Ballatore et al., 2013). The
less acidic hydroxyl group should show improved pharmaco-
kinetic and bioavailability profiles with respect to inhibitors
with a carboxylic acid group.
The incorporation of halogen atoms into a lead drug
candidate results in analogues that are usually more lipophilic;
consequently, they are used to improve penetration through
lipid membranes and tissues. Halogenation also enhances
blood–brain barrier permeability and this is a prerequisite
for drugs that need to target the central nervous system
(Hernandes et al., 2010; Parisini et al., 2011). A first step for
JF0064 drug optimization would be to assess whether the F
atom is the best suited halogen or whether it could be replaced
by a Cl or Br atom (which are of larger size and increasing
hydrophobicity; Vallejos et al., 2012). A second step would be
to remove or to replace one or more halogen atoms in the
phenol moieties, thus checking their importance in the inter-
action with the AR/AKR1B10 inhibitor-binding pocket. This
removal/replacement would diminish the acidic character of
the hydroxyl group in order to fine-tune the pharmacokinetic
properties: on increasing the pKa value from nearly 5.5 in
JF0064 to 7, the compound would become uncharged in
circulation (thus improving its ability to cross biological
membranes) and charged once bound to the protein (the pKa
of the compound would decrease in this environment analo-
gously to the case of cyclic imides; El-Kabbani & Podjarny,
2007).
It is known that any ligand-binding event displaces water
molecules from a binding site. In structure-based drug design
(SBDD), most of these water molecules are never explicitly
considered because they are highly disordered and therefore
rarely observed crystallographically. However, in this work,
the ultrahigh resolution of the AR–JF0064 complex allows an
estimation of whether these water molecules are displaceable
by a given ligand moiety. Indeed, in the AR complex, two of
the water molecules in the vicinity of the outer hydroxyl
group, HOH-95 and HOH-71 (Fig. 4a), present very low B
factors (11 A˚2). While these waters seem to be conserved in
the AKR1B10 model obtained by MD, the surrounding amino
acids in AR and AKR1B10 are different (Val297, Ala299
and Ser302 in AR versus Ala298, Asn300 and Gln303 in
AKR1B10). This opens the possibility of modifying the inhi-
bitor to occupy these positions with groups that make specific
interactions, either with AR or with AKR1B10, to increase the
selectivity and potency. In summary, analysis of the inhibition
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properties of the JF compound series with AR and AKR1B10
has permitted the discovery of a novel lead compound,
JF0064, which is able to inhibit both AR and AKR1B10.
In this regard, some disease conditions overexpressing both
proteins, such as hepatocellular carcinoma (Cao et al., 1998;
Zeindl-Eberhart et al., 2004), could benefit from the use of
a single compound to inhibit the two enzymes. This idea, to
design a drug with pronounced target selectivity but covering
one or more targets of interest, has lately gained credence
(Huggins et al., 2012). Furthermore, the screening performed
here, complemented by structural data, has provided signifi-
cant insights into the SBDD of potent and selective AR and
AKR1B10 inhibitors.
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